AllSci News
Jocasta cuts Unity from α-klotho IP chain with direct UCSF deal
Scottsdale, Arizona-based Jocasta Neuroscience has secured a direct license from the University of California, San Francisco (UCSF) covering α-klotho-based...
CoRegen takes CRISPR-edited Tregs into first human cancer trial
A novel approach to cancer immunotherapy that inverts the conventional role of regulatory T cells has entered first-in-human testing, with CoRegen, Inc....
KaliVir raises USD 14m as oncolytic virus clears first IV cohort
Pittsburgh, Pennsylvania-based KaliVir Immunotherapeutics, Inc. has closed a USD 14 million extension of its Series A financing to fund continued clinical...
Tolerance Bio licenses clinical-stage IL-7 therapy to enter thymic function studies
Philadelphia-based Tolerance Bio has licensed efineptakin alfa (NT-I7), a long-acting IL-7 fusion protein, from South Korea-based NeoImmuneTech (KOSDAQ:...
Enhertu becomes first HER2-directed therapy to beat chemoimmunotherapy in 1st-line lung cancer
Trastuzumab deruxtecan (Enhertu) has become the first HER2-directed therapy to demonstrate a progression-free survival benefit over the global standard of...
Regeneron halts first-in-human REGN7041 trial after safety event
A Phase I/II clinical trial of REGN7041, an anti-CD3 monoclonal antibody developed by Regeneron Pharmaceuticals, has been terminated after enrolling just...
Genentech doubles down on IDEAYA’s PRMT5 strategy with KRAS G12D combo
South San Francisco-based IDEAYA Biosciences (Nasdaq: IDYA) and Genentech, a member of the Roche Group, announced a clinical collaboration to evaluate...
BioArctic expands BrainTransporter platform from neurodegeneration to glioblastoma with Mesenkia collaboration
Sweden-based BioArctic AB (Nasdaq Stockholm: BIOA B) and preclinical-stage Mesenkia Therapeutics have signed a research collaboration agreement to generate...
Pfizer drops IgAN candidate PF-07985631 over benefit-risk assessment
Pfizer's first-in-human trial of PF-07985631, a biologic in development for IgA nephropathy (IgAN), has been terminated after enrolling only 9 participants,...
REDNVIA terminates Phase II/III trial of DPP-4 inhibitor evogliptin in aortic stenosis
A randomized, placebo-controlled trial evaluating the DPP-4 inhibitor evogliptin (DA-1229) as a potential therapy for calcific aortic valve disease has been...
Merck, Moderna neoantigen therapy delivers landmark Phase III melanoma win
A Phase III trial of intismeran autogene, the mRNA-based individualized neoantigen therapy co-developed by Merck (NYSE: MRK) and Moderna (Nasdaq: MRNA), has...
University of Milan team turns senolytic drug against hard-to-treat mycobacterial infection
A senolytic drug already in clinical development for oncology can reduce bacterial burden in a notoriously treatment-resistant mycobacterial infection by...
NIH funds new blood biomarkers to track islet dysfunction in type 1 diabetes
Battelle Pacific Northwest Laboratories has received a USD 1.92 million NIH R01 grant from the National Institute of Diabetes and Digestive and Kidney...
Stanford moving novel oral influenza antiviral toward IND with NIAID backing
Stanford University has received a USD 1.27 million NIAID R56 grant to advance a novel oral small molecule antiviral against influenza A virus (IAV) toward...
Lilly completes USD 10m payment for preclinical Alzheimer's GSM from AlzeCure
Eli Lilly has received full delivery of the USD 10 million upfront payment under its collaboration and out-licensing agreement with Sweden-based AlzeCure...
The AllSci Brief
Free, systematic R&D and deal news. Daily.